Diazoxide choline controlled release - Soleno Therapeutics

Drug Profile

Diazoxide choline controlled release - Soleno Therapeutics

Alternative Names: DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release; Diazoxide-choline-controlled-release-Essentialis

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Essentialis
  • Developer Essentialis; Soleno Therapeutics
  • Class Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Diagnostic agents; Peripheral vasodilators; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prader-Willi syndrome
  • No development reported Hypertriglyceridaemia
  • Discontinued Hypoglycaemia; Obesity

Most Recent Events

  • 06 Sep 2018 Soleno Therapeutics receives protocol amendment from the US FDA for the phase III DESTINY PWS trial for Prader-Willi syndrome
  • 04 Sep 2018 Soleno Therapeutics has patent protection for diazoxide choline controlled release in USA
  • 04 Sep 2018 Soleno Therapeutics initiates enrolment in a phase III clinical trial for Prader-Willi Syndrome (PWS) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top